Gene Repair of iPSC Line with GARS (G294R) Mutation of CMT2D Disease by CRISPR/Cas9

Abstract

Objective

Charcot-Marie-Tooth disease (CMT) severely affects patient activity, and may cause disability. However, no clinical treatment is available to reverse the disease course. The combination of CRISPR/Cas9 and iPSCs may have therapeutic potential against nervous diseases, such as CMT.

Methods

In the present study, the skin fibroblasts of CMT type 2D (CMT2D) patients with the c.880G>A heterozygous nucleotide mutation in the GARS gene were reprogrammed into iPSCs using three plasmids (pCXLE-hSK, pCXLE-hUL and pCXLE-hOCT3/4-shp5-F). Then, CRISPR/Cas9 technology was used to repair the mutated gene sites at the iPSC level.

Results

An iPSC line derived from the GARS (G294R) family with fibular atrophy was successfully induced, and the mutated gene loci were repaired at the iPSC level using CRISPR/Cas9 technology. These findings lay the foundation for future research on drug screening and cell therapy.

Conclusion

iPSCs can differentiate into different cell types, and originate from autologous cells. Therefore, they are promising for the development of autologous cell therapies for degenerative diseases. The combination of CRISPR/Cas9 and iPSCs may open a new avenue for the treatment of nervous diseases, such as CMT.

Keywords

Charcot-Marie-Tooth disease / GARS / CRISPR/Cas9 / iPSCs / gene therapy

References

[1] RossorAM, PolkeJM, HouldenH, et al.. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol, 2013, 9(10): 562-571

[2] PerettiA, PerieM, VincentD, et al.. LRSAM1 variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2. Eur J Hum Genet, 2019, 27(9): 1406-1418

[3] SleighJN, DawesJM, WestSJ, et al.. Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations. Proc Natl Acad Sci USA, 2017, 114(16): E3324-E3333

[4] MoZ, ZhaoX, LiuH, et al.. Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy. Nat Commun, 2018, 9(1): 1007

[5] YoshidaY, YamanakaS. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res, 2017, 120(12): 1958-1968

[6] FirthAL, MenonT, ParkerGS, et al.. Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Rep, 2015, 12(9): 1385-1390

[7] GriceSJ, SleighJN, Zameel CaderM. Plexin-Semaphorin Signaling Modifies Neuromuscular Defects in a Drosophila Model of Peripheral Neuropathy. Front Mol Neurosci, 2018, 11: 55

[8] HeW, BaiG, ZhouH, et al.. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature, 2015, 526(7575): 710-714

[9] NiehuesS, BussmannJ, SteffesG, et al.. Impaired protein translation in Drosophila models for Charcot-Marie-Tooth neuropathy caused by mutant tRNA synthetases. Nat Commun, 2015, 6: 7520

[10] RaviB, AntonellisA, SumnerCJ, et al.. Genetic approaches to the treatment of inherited neuromuscular diseases. Hum Mol Genet, 2019, 28(R1): R55-R64

[11] Ortiz-VirumbralesM, MorenoCL, KruglikovI, et al.. CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 (N141I) neurons. Acta Neuropathol Commun, 2017, 5(1): 77-96

[12] OuZ, NiuX, HeW, et al.. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human beta-thalassemia in Mice. Sci Rep, 2016, 6: 32463

[13] HuX. CRISPR/Cas9 system and its applications in human hematopoietic cells. Blood Cells Mol Dis, 2016, 62(2016): 6-12

[14] SweeneyCL, MerlingRK, De RavinSS, et al.. Gene Editing in Chronic Granulomatous Disease. Methods Mol Biol, 2019, 1982: 623-665

[15] Garcia-LeonJA, VitoricaJ, GutierrezA. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. Future Med Chem, 2019, 11(11): 1305-1322

[16] KumarD, AnandT, KuesWA. Clinical potential of human-induced pluripotent stem cells: Perspectives of induced pluripotent stem cells. Cell Biol Toxicol, 2017, 33(2): 99-112

[17] ChangCW, LaiYS, WestinE, et al.. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9- Enhanced Gene Targeting. Cell Rep, 2015, 12(10): 1668-1677